KOL Insight - Ovarian Cancer

This report provides a comprehensive analysis of the current and emerging targeted therapies in ovarian cancer, including PARP inhibitors, antibody-drug conjugates, and immunotherapy approaches. It examines the evolving treatment landscape, highlights key clinical trial data, and addresses challenges such as drug resistance, toxicity management, and patient selection.

The report also explores the potential of next-generation agents targeting DNA damage repair pathways and novel antigens, offering insights into future directions for optimising therapeutic strategies in both newly diagnosed and relapsed ovarian cancer populations.

Key Questions Answered:

• What are the current standard-of-care targeted therapies for ovarian cancer?
• How are PARP inhibitors (olaparib, rucaparib, niraparib) perceived and utilized in clinical practice?
• Which recent or ongoing clinical trials are most likely to impact ovarian cancer treatment trends?
• What criteria must emerging targeted therapies meet to become preferred options in specific patient segments?
• Which late-stage pipeline products show the most promise for future ovarian cancer treatment?
• How is the ovarian cancer treatment landscape expected to evolve over the next three to five years for both newly diagnosed and relapsed patients?

Key Brands:

Partial List of Participating Experts:

• Professor of Gynecologic Oncology, University of Arizona College of Medicine, Phoenix, AZ, USA
• Professor of Medical Oncology, University College London (UCL) Cancer Institute, London, UK.
• Professor of Medical Oncology, University of Strasbourg/University Hospital Strasbourg, Strasbourg, France.
• Professor, Director of Gynecologic Oncology Clinical Research, Washington University School of Medicine, St. Louis, Missouri, USA
• Professor, Director of Gynecologic Oncology, Ohio State University, James Cancer Center, Columbus, OH, USA
• Professor, Head of the Department of Obstetrics and Gynecology and Gynecologic Oncology, Catholic University of Leuven, Belgium.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.